This trial is testing a new treatment for stage III melanoma that involves two drugs given before surgery, followed by more of one of the drugs or a different drug after surgery.
1 Primary · 10 Secondary · Reporting Duration: Analysis will be performed after 132 events, though not later than after 2 years follow-up of all patients.
420 Total Participants · 2 Treatment Groups
Primary Treatment: Neoadjuvant ipilimumab + nivolumab · No Placebo Group · Phase 3
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: